Breast lymphoscintigraphy for sentinel node identification in breast cancers with clinically-negative axillary nodes

Singapore Medical Journal

Volumn 46, Issue 12, 2005, Pages 688-692

  Namwongprom, Sirianong ^a   Boonyaprapa, S ^a   Ekmahachai, M ^a   Vilasdechanon, N ^a   Somwangprasert, A ^a   Sumitsawan, S ^a   Taya, P ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

Axillary lymph node; Breast cancer; Lymphoscintigraphy; Preoperative breast lymphoscintigraphy; Sentinel lymph node localisation

Indexed keywords

NANOCOLL TC 99M;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER SCINTISCANNING; CANCER SIZE; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LYMPH NODE BIOPSY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MASTECTOMY; PREOPERATIVE EVALUATION; SCINTILLATION CAMERA; SCINTIMAMMOGRAPHY; SENTINEL LYMPH NODE;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; FEMALE; GAMMA CAMERAS; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; TECHNETIUM;

EID: 28844500827     PISSN: 00375675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983; 52:1551-7.
2. Lin PP, Allison DC, Wainstock J, et al. Impact of axillary lymph node dissection on the therapy of breast cancer patients. J Clin Oncol 1993; 11:1536-44.
3. Ivens D, Hoe AL, Podd TJ, et al. Assessment of morbidity from complete axillary dissection. Br J Cancer 1992; 66:136-8.
4. Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer: a review. Cancer 1995; 76:1491-512.
5. Morton DL, Wen D, Cochran AJ. Management of early-stage melanoma by intraoperative lymphatic mapping and selective lymphadenectomy: an alternative to routine elective lymphadenectomy or "watch and wait". Surg Oncol Clin N Am 1992; 1:247-59.
6. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127:392-9.
7. van der Veen H, Hoekstra OS, Paul MA, et al. Gamma-probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy. Br J Surg 1994; 81:1769-70.
8. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 20:391-401.
9. Krag D, Weaver D, Ashikaga T, et al. The sentinel lymph node in breast cancer - a multicenter validation study. N Eng J Med 1998; 339:941-6.
10. Albertini J J, Lyman G H, Cox C, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276:1818-22.
11. Mariotti S, Buonomo O, Guadagni F, et al. Minimal sentinel node procedure for staging early breast cancer. Tumori 2002; 88:S45-7.
12. Cox CE, Pendas S, Cox JM, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 1998; 227:645-53.
13. Sandrucci S, Mussa A. Sentinel lymph node biopsy and axillary staging of T1-T2 NO breast cancer: a multicenter study. Semin Surg Oncol 1998; 15:278-83.
14. Fernandez A, Escobedo A, Benito E, et al. Sentinel node localization in patients with non-palpable breast cancer. Nucl Med Commun 2002; 23:1165-9.
15. Veronesi U, Rilke F, Luini A, et al. Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer 1987; 59:682-7.
16. Zurrida S, Galimberti V, Orvieto E, et al. Radioguided sentinel node biopsy to avoid axillary dissection in breast cancer. Ann. Surg. Oncol 2000; 7:28-31.
17. Bembenek A, Reuhl T, Markwardt J, et al. Sentinel lymph node dissection in breast cancer. Swiss Surg 1999; 5:217-21.
18. Salmon RJ, Fried D. [Demonstration of the sentinel lymph node in axillary dissection for breast cancer]. Presse Med 1998; 27:509-12. French.
19. Veronesi U, Paganelli G, Viale G, et al. Sentinel lymph node biopsy and axillary dissection in breast cancer: results in a large series. J Natl Cancer Inst 1999; 91:368-73.
20. Veronesi U, Zurrida S, Galimberti V. Consequences of sentinel node in clinical decision making in breast cancer and prospects for future studies. Eur J Surg Oncol 1998; 24:93-5.
21. Gulec SA, Moffat FL, Carroll RG, et al. Sentinel lymph node localization in early breast cancer. J Nucl Med 1998; 39:1388-93.
22. Giuliano AE, Dale PS, Turner RR, et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995; 222:394-401.
23. McMasters KM, Giuliano AE, Ross MI, et al. Sentinel-lymph-node biopsy for breast cancer - not yet the standard of care. N Engl J Med 1998; 339:990-5.
24. Tafra L, Lannin DR, Swanson MS, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg 2001; 233:51-9.
25. Orr RK, Hoehn JL, Col NF. The learning curve for sentinel node in breast cancer: practical considerations. Arch Surg 1999; 134:764-7.
26. Cody HS 3rd, Hill AD, Tran KN, et al. Credentialing for breast lymphatic mapping: how many cases are enough? Ann Surg 1999; 229:723-8.
27. Bass SS, Cox CE, Ku NN, et al. The role of sentinel lymph node biopsy in breast cancer. J Am Coll Surg 1999; 189:183-94.
28. Tse NY, Hoh CK, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216:27-34.
29. Schirrmeister H, Kuhn T, Guhlmann A, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001; 28:351-8.
30. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18 FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med 1998; 39:4-8.
31. Adler LP, Faulhaber PF, Schnur KC, et al. Axillary lymph node metastases: screening with [F-18] 2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology 1997; 203:323-7.
32. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996; 23:1588-93.
33. Avril N, Dose J, Janicke F, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996; 88:1204-9.
34. Smith IC, Ogston KN, Whitford P, et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg 1998; 228:220-7.
35. Barranger E, Grahek D, Antoine M, et al. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol 2003; 10:622-7.
36. van der Hoeven JJ, Hoekstra OS, Comans EF, et al. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg 2002; 236:619-24.
37. Guller U, Nitzsche EU, Schirp U, et al. Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet!. Breast Cancer Res Treat 2002; 71:171-3.
38. Yang JH, Nam SJ, Lee TS, et al. Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients. Jpn J Clin Oncol 2001; 31:1-6.
39. Kelemen PR, Lowe V, Phillips N. Positron emission tomography and sentinel lymph node dissection in breast cancer. Clin Breast Cancer 2002; 3:73-7.